Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | ACACB | O00763 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5154682 | 0.94 | NQO1 (0.52) | NQO1GAATSHRTDP1SMN1; SMN2 | |
| SCHEMBL5450460 | 0.89 | RELA (0.59) | NQO1GAASMN1; SMN2RELA | |
| SCHEMBL5450463 | 0.89 | RELA (0.59) | NQO1GAASMN1; SMN2RELA | |
| SCHEMBL7774589 | 0.84 | LMNA (0.49) | LTA4HACACBLMNASMN1; SMN2CA12 | |
| SCHEMBL1823685 | 0.84 | LTA4H (0.48) | TSHRLTA4HSMN1; SMN2 | |
| SCHEMBL8538723 | 0.83 | GLA (0.44) | NQO1GAATSHRTDP1LMNA | |
| SCHEMBL4112906 | 0.83 | MAPT (0.64) | GAATDP1LMNASMN1; SMN2PKM | |
| SCHEMBL17215124 | 0.83 | GAA (0.43) | GAALTA4HPKMPRSS1 | |
| SCHEMBL6573094 | 0.81 | GAA (0.42) | GAATDP1SMN1; SMN2PKM | |
| SCHEMBL28110894 | 0.81 | GAA (0.42) | GAATDP1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-58131931-A | — | — | None | — | — | JP | disclosed |
| CN-116854668-B | Phthalazinone compound, pharmaceutical composition and application thereof | 中国药科大学 | 2025-02-07 | — | — | CN | disclosed |
| CN-114573490-B | Diaryl-2H-aziridine compounds, preparation method and application thereof | 复旦大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-116854668-A | Phthalazinone compound, pharmaceutical composition and application thereof | 中国药科大学 | 2023-10-10 | — | — | CN | disclosed |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2023-01-24 | — | — | US | disclosed |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2023-01-03 | — | — | US | disclosed |
| CN-114573490-A | diaryl-2H-aziridines and diaryl aziridines compounds, preparation method and application thereof | 复旦大学 | 2022-06-03 | — | — | CN | disclosed |
| US-20210323978-A1 | ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-0161921-A2 | Improvements relating to pesticides | BTG INTERNATIONAL LIMITED (GB) | 1985-11-21 | — | — | EP | disclosed |
| WO-1985004651-A1 | IMPROVEMENTS RELATING TO PESTICIDES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1985-10-24 | — | — | WO | disclosed |
| US-4447454-A | Analgetic compounds, compositions and process of treatment | THE UPJOHN COMPANY (US) | 1984-05-08 | — | — | US | disclosed |
| JP-S58131931-A | 2-(4-ETHOXYPHENYL)-2-METHYLPROPYL ALCOHOL AND ITS PREPARATION | MITSUI TOATSU CHEM INC | 1983-08-06 | — | — | JP | disclosed |
| US-4113866-A | ANALGETIC COMPOUNDS, COMPOSITIONS AND PROCESS OF TREATMENT | THE UPJOHN COMPANY (US) | 1978-09-12 | — | — | US | disclosed |
| US-4107189-A | 2,3-DIPHENYLACRYLONITRILES, DYNAMIC SCATTERING IN ELECTRICAL FIELD | U.S. PHILIPS CORPORATION (US) | 1978-08-15 | — | — | US | disclosed |
| US-3984559-A | Compositions comprising tetramic acid analogs of pulvinic acid and methods of combating arthritis | SMITHKLINE CORPORATION (US) | 1976-10-05 | — | — | US | disclosed |
| US-3947580-A | Anti-arthritic compositions comprising N-heterocyclic pulvinic acid amides and methods of producing anti-arthritic activity | SMITHKLINE CORPORATION (US) | 1976-03-30 | — | — | US | disclosed |
| US-3944571-A | ANTIARTHRITIC | SMITHKLINE CORPORATION (US) | 1976-03-16 | — | — | US | disclosed |
| US-3931207-A | ANTIARTHRITIC | SMITHKLINE CORPORATION (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | NQO1 531/4885GAA 2713/4885TSHR 4461/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | NQO1 531/4885GAA 2713/4885TSHR 4461/4885 |
| US-20210323978-A1 | ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, USP3, SENP7 | NQO1 2420/4885GAA 2423/4885TSHR 2826/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | NQO1 1527/4885GAA 2581/4885TSHR 4307/4885 |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | NQO1 1527/4885GAA 2581/4885TSHR 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.